Sequencing Reagents Market size was valued at USD 7.93 billion in 2024 and is likely to reach USD 59.71 billion by the end of 2037, expanding at around 16.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of sequencing reagents is assessed at USD 9 billion.
The quick development in sequencing technology will primarily propel the market of market by the end of 2036. Illumina sequencing creation, sequencing by blend (SBS), may be an extensively approved next-generation sequencing (NGS) creation across the globe. Illumina sequencing instruments and reagents back considerably parallel sequencing utilizing an exclusive plan that acknowledges single bases as they are connected into growing DNA strands.
Another reason behind the massive growth of the sequencing reagents market is the limited costs of genetic sequencing. The HGP included beginning with mapping and after that sequencing the human genome. The previous was required at the time since there was something else no 'framework' for organizing the real sequencing or the coming about arrangement information. The maps of the human genome served as 'scaffolds' on which to put through personal portions of amassed DNA grouping. These genome-mapping endeavors were very costly but were basic at the time for producing an exact genome arrangement. It is troublesome to appraise the costs related to the 'human genome mapping phase' of the HGP, but it was certainly within the numerous tens of millions of dollars. The evaluation has taken a toll on creating that beginning 'draft' human genome arrangement is approximately USD 300 million around the world, of which NIH generally has 50-60%.
Growth Drivers
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
16.8% |
Base Year Market Size (2024) |
USD 7.93 billion |
Forecast Year Market Size (2037) |
USD 59.71 billion |
Regional Scope |
|
Technology (Next Generation Sequencing, Sanger Sequencing, Third Generation Sequencing)
The next-generation sequencing segment in the will grow the most by the forecast period and will hold almost 45% in the sequencing reagents market because of its high possibility for the growth of companion diagnostics and customized medicine for the treatment of chronic diseases. Next-generation sequencing (NGS) may empower more centered and profoundly personalized cancer treatment, with the National Comprehensive Cancer Arrange and European Society for Restorative Oncology rules presently prescribing NGS for everyday clinical hone for a few tumor sorts. Be that as it may, NGS usage, and thus persistent get to, changes over Europe; a multi-stakeholder collaboration is required to set up the conditions required to progress this disparity. In that respect, the analysts set up European Collusion for Customized Pharmaceutical (EAPM)-led master boards amid the primary half of 2021, counting key partners from over 10 European countries covering restorative, financial, quiet, industry, and legislative mastery. NGS tests are ordinarily run to realize a foreordained scope, which is the normal profundity of sequencing overall focused on genome positions. Scope at any genome arrangement can be calculated, after mapping sequencing peruses to the reference genome, by tallying the number of autonomous peruses that cover that position and thus will propel the sequencing reagents market.
Application (Clinical Investigation, Oncology, Forensics & Agrigenomics, Virology, RNA Sequencing, Metagenomics)
The oncology segment is expected to hold around 38% share of the global sequencing reagents market by 2037, owing to the increasing implementation of next-generation sequencing for cancer diagnosis and treatment across the world. Next-generation sequencing testing selection rates have expanded in later a long time, with rates for progressed non–small cell lung cancer (aNSCLC), metastatic colorectal cancer (mCRC), metastatic breast cancer (mBC), and progressed melanoma expanding from less than 1% in 2011 to approximately 40% in 2022. Thus, it will help this segment to have the largest growth in the sequencing reagents market.
Our in-depth analysis of the global sequencing reagents market includes the following segments:
Type |
|
Technology |
|
Application |
|
Reagent Type |
|
End-Use Industry |
|
North American Market
The sequencing reagents market in the North America region will have the biggest growth during the forecast period with a revenue share of around 34%. This growth will be noticed owing to the region’s advanced healthcare system. The Joined together States positions 4th in the World Record of Healthcare Development, with an in-general score of 54.96, behind as it were Switzerland, Germany, and the Netherlands. Americans are as a rule the primary to pick up major unused therapeutic propels, progresses regularly found at American colleges and created by American companies. As a result, the U.S. positioned to begin with for both Choice (57.67) and Science & Innovation (75.15).
European Market
The sequencing reagents market in the Europe region will also encounter huge growth during the forecast period and will hold the second position owing to the rising concentration on customized medicine and high healthcare investment in countries like the United Kingdom and Germany. With its 743 million inhabitants spread over 44 nations, counting the 27 countries inside the EU, Europe may be a critical player within the worldwide financial landscape. Moreover, by 2040 care will be sorted out around the citizens instead of around the teachers that drive the existing healthcare frameworks. These changes will influence the businesses and working models of all partners, counting unused non-traditional companies entering the healthcare space. Thus, it will help the European region to have significant growth in the sequencing reagents market.
Total Genomics, the US backup of Chinese next-generation sequencing instrumented organization MGI Tech, disclosed its most noteworthy throughput sequencer at the yearly assembly of Propels in Genome Science and Innovation.
Thermo Fisher Scientific Inc, the world pioneer in serving science, recently reported the dispatch of an unused CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas' 10th syndicated illness registry and addresses a neglected requirement for real-world proof (RWE) related to the clinical and patient-reported results of patients with GPP.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?